Thromboembolism in lung cancer - An area of urgent unmet need

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 275-280

  Alexander, M ^a,b   Kirsa, S ^a   Wolfe, R ^b   MacManus, M ^a   Ball, D ^a,c   Solomon, B ^a,c   Burbury, K ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Lung cancer; Thromboembolism; Thromboprophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; PEMETREXED;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOBILIZATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; COMPLICATION; LUNG TUMOR; MIDDLE AGED; NON SMALL CELL LUNG CANCER; RISK FACTOR; SMALL CELL LUNG CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SMALL CELL LUNG CARCINOMA; THROMBOEMBOLISM;

EID: 84901947942     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.009     Document Type: Article

References (46)

1. Chew H.K., Wun T., Harvey D., Zhou H., White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006, 166(4):458-464.
2. Blom J.W., Osanto S., Rosendaal F.R. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004, 2(10):1760-1765.
3. Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293(6):715-722.
4. Agnelli G., Verso M., Ageno W., Imberti D., Moia M., Palareti G., et al. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008, 121(5):605-610.
5. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007, 110(10):2339-2346.
6. Kuderer N.M., Ortel T.L., Francis C.W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009, 27(29):4902-4911.
7. Akl E.A., Terrenato I., Barba M., Sperati F., Sempos E.V., Muti P., et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008, 168(12):1261-1269.
8. Cohen A.T., Zaw H.M., Alikhan R. Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Semin Hematol 2001, 38(2 Suppl. 5):31-38.
9. Mismetti P., Laporte S., Darmon J.Y., Buchmuller A., Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001, 88(7):913-930.
10. Chew H.K., Davies A.M., Wun T., Harvey D., Zhou H., White R.H. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008, 6(4):601-608.
11. Stein P.D., Beemath A., Meyers F.A., Skaf E., Sanchez J., Olson R.E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006, 119(1):60-68.
12. Horsted F., West J., Grainge M.J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012, 9(7):e1001275.
13. Hicks L.K., Cheung M.C., Ding K., Hasan B., Seymour L., Le Maitre A., et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009, 115(23):5516-5525.
14. Tagalakis V., Levi D., Agulnik J.S., Cohen V., Kasymjanova G., Small D. High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2007, 2(8):729-734.
15. Connolly G.C., Dalal M., Lin J., Khorana A.A. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer 2012, 78(3):253-258.
16. Khorana A.A., Dalal M., Lin J., Connolly G.C. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013, 119(3):648-655.
17. Sallah S., Wan J.Y., Nguyen N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002, 87(4):575-579.
18. Heit J.A., Melton L.J., Lohse C.M., Petterson T.M., Silverstein M.D., Mohr D.N., et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001, 76(11):1102-1110.
19. Khorana A.A., Francis C.W., Culakova E., Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005, 104(12):2822-2829.
20. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007, 5(March (3)):632-634.
21. Agnelli G., Gussoni G., Bianchini C., Verso M., Mandala M., Cavanna L., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009, 10(10):943-949.
22. Haas S.K., Freund M., Heigener D., Heilmann L., Kemkes-Matthes B., von Tempelhoff G.F., et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012, 18(2):159-165.
23. Agnelli G., George D.J., Fisher W., Kakkar A.K., Lassen M.R., Mismetti P., et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. ASCO Meeting Abs 2011, 29(15 Suppl):LBA9014.
24. Toledano T.H., Kondal D., Kahn S.R., Tagalakis V. The occurrence of venous thromboembolism in cancer patients following major surgery. Thromb Res 2012, 19(12):797-799.
25. National Health and Medical Research Council Stop the clot: integrating VTE prevention guideline recommendations into routine hospital care 2011, National Health and Medical Research Council, Melbourne, Available from http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp134_stop_the_clot_3rd_ed.pdf. 3rd ed.
26. Khorana A.A., Streiff M.B., Farge D., Mandala M., Debourdeau P., Cajfinger F., et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009, 27(29):4919-4926.
27. Lyman G.H., Kuderer N.M. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res 2010, 125(2):70029-70033.
28. Streiff M.B. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010, 125(2). 70030-X.
29. Mandalà M., Falanga A., Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011, 22(Suppl. 6):vi85-vi92. Group ObotEGW.
30. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(6 Suppl):381S-453S.
31. Agnelli G., Bolis G., Capussotti L., Scarpa R.M., Tonelli F., Bonizzoni E., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006, 243(1):89-95.
32. National Statement on Ethical Conduct in Human Research The National Health and Medical Research Council, the Australian Research Council and the Australian Vice-Chancellors' Committee 2007, (Updated May 2013).
33. World medical association declaration of helsinki: Ethical principles for medical research involving human subjects. JAMA. Published online October 19, 2013. doi:. http://10.1001/jama.2013.281053.
34. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
35. van Belle G. Statistical rules of thumb 2008, John Wiley & Sons, Inc. 2nd ed.
36. StataCorp STATA survival analysis and epidemiological tables reference manual 2011, StataCorp LP., College Station, Texas.
37. Carrier M., Righini M., Wells P.S., Perrier A., Anderson D.R., Rodger M.A., et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010, 8(8):1716-1722.
38. Malgor R.D., Bilfinger T.V., Labropoulos N. A systematic review of pulmonary embolism in patients with lung cancer. Ann Thorac Surg 2012, 94(1):311-316.
39. Cronin C.G., Lohan D.G., Keane M., Roche C., Murphy J.M. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgen 2007, 189(1):162-170.
40. Gary T., Belaj K., Steidl K., Pichler M., Eisner F., Stoger H., et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. Br J Cancer 2012, 107(8):1244-1248.
41. Beck-Razi N., Kuzmin A., Koren D., Sarig G., Brenner B., Haim N., et al. Asymptomatic deep vein thrombosis in advanced cancer patients: the value of venous sonography. J Clin Ultrasound 2010, 38(5):232-237.
42. Dentali F., Ageno W., Becattini C., Galli L., Gianni M., Riva N., et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 2010, 125(6):518-522.
43. Tiseo M., Bersanelli M., Pesenti Barili M., Bartolotti M., De Luca G., Gelsomino F., et al. Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients. Tumori 2012, 98(5):594-600.
44. Austin P.C. Generating survival times to simulate Cox proportional hazards models with time-varying covariates. Stat Med 2012, 31(29):3946-3958.
45. Beyersmann J., Wolkewitz M., Schumacher M. The impact of time-dependent bias in proportional hazards modelling. Stat Med 2008, 27(30):6439-6454.
46. Dekker F.W., de Mutsert R., van Dijk P.C., Zoccali C., Jager K.J. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int 2008, 74(8):994-997.